Results 291 to 300 of about 87,481 (331)

Correlating membrane‐protein dynamics with function: Integrating bioinformatics, molecular dynamics, and single‐molecule FRET

open access: yesProtein Science, Volume 34, Issue 11, November 2025.
Abstract We present a strategy that deploys structural bioinformatics, molecular simulation, and single‐molecule Förster Resonance Energy Transfer (FRET) microscopy for observing the ligand‐dependent conformational dynamics of integral membrane proteins in situ.
Hugh R. Higinbotham   +2 more
wiley   +1 more source

Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 137, Issue 5, November 2025.
Structure of lisdexamfetamine dimesylate, its active metabolite d‐amphetamine and the essential amino acid l‐lysine, along with the mechanism of action and primary pharmacological and adverse effects associated with lisdexamfetamine dimesylate. TAAR1, trace amine‐associated receptor; VMAT, vesicular monoamine transporter; DAT, dopamine transporter; NAT,
Mariana Silva‐Carvalho   +3 more
wiley   +1 more source

Mass Balance and Metabolism of 14C‐Atogepant in Healthy Male Participants: Findings of a Phase 1 Clinical Trial

open access: yesClinical and Translational Science, Volume 18, Issue 11, November 2025.
ABSTRACT Atogepant, a calcitonin gene‐related peptide (CGRP) receptor antagonist, is approved for the preventive treatment of migraine in adults. This open‐label, phase 1 study examined radiolabeled atogepant (14C‐atogepant) metabolism, elimination, and mass balance after a single dose (50 mg, ~200 μCi) in healthy adult males.
Ramesh R. Boinpally   +2 more
wiley   +1 more source

A Phase 1 Study to Assess the Effect of Fruquintinib on the Pharmacokinetics of P‐gp and BCRP Substrates in Healthy Subjects

open access: yesClinical and Translational Science, Volume 18, Issue 11, November 2025.
ABSTRACT Fruquintinib, a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (−1, −2, and −3), is approved for previously treated metastatic colorectal cancer. This phase 1, two‐part, two‐period, fixed‐sequence study (NCT05368805) evaluated the potential inhibitory effect of fruquintinib (5 mg) on the ...
Martha Gonzalez   +5 more
wiley   +1 more source

Using the PET/CT radiotracer [<sup>68</sup>Ga]Ga-DOTA-mDesmo to target V1b receptors and localize corticotropinoma in Cushing's disease. [PDF]

open access: yesCommun Med (Lond)
Pandey S   +8 more
europepmc   +1 more source

A somatic multiple myeloma mutation unravels a mechanism of oligomerization‐mediated product inhibition in GGPPS

open access: yesThe FEBS Journal, Volume 292, Issue 21, Page 5802-5817, November 2025.
Geranylgeranyl diphosphate synthase (GGPPS) plays a key role in multiple myeloma biology. Using crystallography, mass spectrometry, and fluorescence spectroscopy, this study shows that a somatic multiple myeloma cell line mutation destabilizes inter‐dimer interactions, resulting in increased GGPPS activity by facilitating product releas.
Ruba Yehia   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy